CTLA4 and cancer: The remarkable clinical results of blocking immune inhibitory checkpoints such as programmed cell death protein (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in some cancers during the last decade have propelled immune checkpoint blockade (ICB)-based immunotherapy into popularity.